DOSAGE REGIMENS FOR HCV COMBINATION THERAPY COMPRISING BI201335, INTERFERON ALPHA AND RIBAVIRIN

摘要

Patent No. 598465 Disclosed is the use of a therapeutic combination comprising: (a) Compound (1) or a pharmaceutically acceptable salt thereof: (b) an interferon alpha; and (c) ribavirin, in the preparation of a medicament for treating hepatitis C viral (HCV) infection or alleviating one more symptoms thereof in a patient, wherein the first dose of Compound (1), or a pharmaceutically acceptable salt thereof, is formulated for administration to the patient double in quantity by weight to the subsequent doses thereof.